Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. It offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for ERIS
Revenue projections for ERIS

Investors may react cautiously to news that ERIS's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 0.74100
forwardPE 23.87298
debtToEquity 60.54500
earningsGrowth 2.00000
revenueGrowth 0.07100
grossMargins 0.74458
operatingMargins 0.27117
trailingEps 45.23000
forwardEps 61.14444

ERIS's Forward PE being in a good range indicates that the stock is valued appropriately based on its earnings. This suggests the stock is not overpriced and leaves room for growth, providing investors with an opportunity for potential appreciation in value.
ERIS's positive gross and operating margins suggest the company is performing profitably. These margins reflect efficient cost management and strong revenue generation, signaling healthy financial performance and operational effectiveness.
ERIS's forward EPS surpassing its trailing EPS signals that the company is anticipated to be more profitable this year than last. This growth expectation highlights ERIS's potential for increased earnings and a stronger financial performance in the upcoming year.

Price projections:

Price projections for ERIS
Price projections for ERIS

Eris Lifesciences Limited's price has consistently been situated near the lower end of expected values. This ongoing trend may reflect investor skepticism about the company's growth potential and overall performance.

Recommendation changes over time:

Recommendations trend for ERIS
Recommendations trend for ERIS


Analysts are favoring Eris Lifesciences Limited with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider Eris Lifesciences Limited as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.